Rocket Pharmaceuticals Reaches FDA Alignment on Phase 2 Trial Path for Danon Disease

Filing content

The company reached alignment with the FDA on key elements of the Phase 2 pivotal trial for RP-A501, including the patient population and primary endpoints.